Compare · head to head
Enanta Pharmaceuticals vs Exelixis
Exelixis ranks higher overall — 360 rank 96 vs 62.
Exelixis leads on Value (65 vs 48), Quality (82 vs 52) and Safety (64 vs 47). Enanta Pharmaceuticals leads on Growth (59 vs 49) and Sentiment (57 vs 46).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Small | Large |
| ISIN | US29251M1062 | US30161Q1040 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | — | |
| Ranks | ||
| 360 | 62 | 96 |
| Value | 48 | 65 |
| Quality | 52 | 82 |
| Growth | 59 | 49 |
| Safety | 47 | 64 |
| Sentiment | 57 | 46 |
| Quality details | ||
| Profitability | 55 | 96 |
| Cash Truth | 48 | 68 |
Enanta Pharmaceuticals vs Mirum PharmaceuticalsEnanta Pharmaceuticals vs ModernaEnanta Pharmaceuticals vs Krystal BiotechEnanta Pharmaceuticals vs Puma BiotechnologyAdd a third stock →
Full analyses: Enanta Pharmaceuticals · Exelixis
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100